Pathstone Holdings’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Pathstone Holdings’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-5,000	Closed	-$333K	–	2355
2024 Q4	$333K	Sell	5,000 -5,000	-50%	-$345K	﹤0.01%	1912
2024 Q3	$698K	Hold	10,000	–	–	﹤0.01%	1554
2024 Q2	$648K	Buy	10,000 +5,000	+100%	+$317K	﹤0.01%	1559
2024 Q1	$324K	Hold	5,000	–	–	﹤0.01%	1903
2023 Q4	$329K	Buy	+5,000	New	+$291K	﹤0.01%	1760

Other funds holding PBE

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

Pathstone Holdings's PBE Position: Q1 2025 in Review

Pathstone Holdings sold out of Invesco Biotechnology & Genome ETF (PBE) in Q1 2025, closing a stake of 5,000 shares — an estimated $333K sold.

Pathstone Holdings first reported a position in PBE in Q4 2023 and held it in 5 quarters. The position peaked at $698K in Q3 2024. 94 funds tracked by Wall St. Rank hold PBE as of Q1 2025.

Pathstone Holdings reported no remaining Invesco Biotechnology & Genome ETF position as of Q1 2025 after selling out during the quarter.
Pathstone Holdings sold 5,000 Invesco Biotechnology & Genome ETF shares in Q1 2025, an estimated $333K.
Pathstone Holdings first reported a position in Invesco Biotechnology & Genome ETF in Q4 2023 and held it in 5 quarters.
Pathstone Holdings's Invesco Biotechnology & Genome ETF position peaked at $698K in Q3 2024.
94 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2025.

Based on Pathstone Holdings's 13F filing for Q1 2025, filed 15 May 2025.